Publications by authors named "Michaela Obersriebnig"
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial.
Lancet Infect Dis
November 2024
Article Synopsis
- - The study evaluated the safety and effectiveness of a booster dose of VLA15, an investigational Lyme disease vaccine, after previously completing the primary vaccination series, as Lyme borreliosis cases are on the rise and effective vaccines are lacking.
- - Conducted as a randomized, placebo-controlled trial, the research involved healthy adults aged 18-65 from five US centers, who received either 135 μg or 180 μg of VLA15 or placebo over an 18-month period before the booster was administered.
- - Results focused on assessing the booster dose's immunogenicity and safety, with monitoring conducted by impartial groups to ensure accurate data collection, and the study is registered and completed under ClinicalTrials.gov (NCT
Article Synopsis
- A new preventive vaccine for Lyme borreliosis, VLA15, targeting key Borrelia outer surface proteins, is being studied due to rising infection rates and the challenges in timely diagnosis and treatment.
- Two phase 2 clinical trials were conducted on healthy adults to determine the optimal vaccine dosage and schedule, with participants receiving varying dosages (90 μg, 135 μg, or 180 μg) via injections.
- The primary goal of the studies was to measure the vaccine's effectiveness based on the levels of specific antibodies (IgG) one month after the final dose, ensuring rigorous safety and randomization protocols throughout the trials.
Background: Zika virus (ZIKV) is an emerging public health threat, rendering development of a safe and effective vaccine against the virus a high priority to face this unmet medical need. Our vaccine candidate has been developed on the same platform used for the licensed vaccine IXIARO®, a vaccine against Japanese Encephalitis virus, another closely related member of the Flaviviridae family.
Methods: Between 24 February 2018 and 16 November 2018, we conducted a randomized, observer-blinded, placebo controlled, single center phase 1 study to assess the safety and immunogenicity of an adjuvanted, inactivated, purified whole-virus Zika vaccine candidate in the USA.
Outstanding questions in the chromatin field bear on how large heterochromatin domains are formed in space and time. Positive feedback, where histone-modifying enzymes are attracted to chromosomal regions displaying the modification they catalyse, is believed to drive the formation of these domains; however, few quantitative studies are available to assess this hypothesis. Here we quantified the de novo establishment of a naturally occurring ∼20-kb heterochromatin domain in fission yeast through single-cell analyses, measuring the kinetics of heterochromatin nucleation in a region targeted by RNAi and its subsequent expansion.
View Article and Find Full Text PDF